Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
HIV prevention
Pharma
With FDA nod, Gilead adds twice-yearly option to PrEP landscape
The drug, branded as Yeztugo, becomes the longest-acting agent in HIV prevention.
Zoey Becker
Jun 18, 2025 2:32pm
Potential US budget cuts have limited impact on Gilead: analysts
Mar 26, 2025 2:47pm
Gilead's PrEP shows early promise in once-yearly dosing
Mar 11, 2025 2:30pm
GSK questions Gilead's potential dominance of the PrEP market
Feb 6, 2025 2:20pm
Rubio allows medicine supplies to resume amid aid freeze: reports
Jan 29, 2025 9:12am
GSK to triple long-acting Apretude supply to boost global access
Oct 7, 2024 10:56am
